Portfolio Sync Solutions
Streamline your investment strategy with our portfolio synchronization tools. Seamlessly manage and track your holdings across platforms for enhanced
GET STARTEDActual EPS
Alnylam Pharmaceuticals, Inc. Analyst EPS Estimates
| Quarter | Number of Estimates | Low Estimate | High Estimate | Average Estimate |
|---|---|---|---|---|
| Q1 2025 | 6 | -$1.39 | -$0.51 | -$0.89 |
| Q2 2025 | 13 | -$4.62 | $4.49 | -$0.66 |
| Q3 2025 | 11 | -$0.51 | -$0.38 | -$0.44 |
| Q4 2025 | 6 | $0.49 | $0.66 | $0.57 |
| Q1 2026 | 5 | -$0.32 | -$0.24 | -$0.28 |
| Q2 2026 | 5 | -$0.02 | -$0.02 | -$0.02 |
| Q3 2026 | 5 | $0.20 | $0.27 | $0.23 |
| Q4 2026 | 5 | $0.63 | $0.84 | $0.73 |
| Q1 2027 | 5 | $0.09 | $0.12 | $0.10 |
| Q2 2027 | 5 | $0.21 | $0.28 | $0.24 |
| Q3 2027 | 5 | $0.37 | $0.50 | $0.43 |
| Q4 2027 | 5 | $0.43 | $0.57 | $0.50 |
Alnylam Pharmaceuticals, Inc. Earnings Date And Information
Alnylam Pharmaceuticals, Inc. last posted its earnings results on Thursday, May 1st, 2025. The company reported $-0.01 earnings per share for the quarter, topping analysts' consensus estimates of $-0.89002 by $0.88002. The company had revenue of 594.19 M for the quarter and had revenue of 2.25 B for the year. Alnylam Pharmaceuticals, Inc. has generated $-2 earnings per share over the last year ($-2.16 diluted earnings per share) and currently has a price-to-earnings ratio of -148.43. Alnylam Pharmaceuticals, Inc. has not formally confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 30th, 2025 based on prior year's report dates.
Alnylam Pharmaceuticals, Inc. Earnings History by Quarter
| Date | Quarter | Consensus Estimate | Reported EPS | Beat/Miss | Revenue Estimate | Actual Revenue |
|---|---|---|---|---|---|---|
| 05/01/2025 | Q1 2025 | -$0.89 | -$0.44 | 0.45 | $585.14 M | $594.19 M |
| 02/13/2025 | Q4 2024 | -$0.62 | -$0.65 | -0.03 | $582.61 M | $593.17 M |
| 10/31/2024 | Q3 2024 | -$0.92 | -$0.87 | 0.05 | $532.91 M | $500.92 M |
| 08/01/2024 | Q2 2024 | -$1.07 | -$0.13 | 0.94 | $447.22 M | $659.83 M |
| 05/02/2024 | Q1 2024 | -$1.12 | -$0.52 | 0.6 | $428.01 M | $494.33 M |
| 02/15/2024 | Q4 2023 | -$1.20 | -$1.10 | 0.1 | $436.92 M | $439.72 M |
| 11/02/2023 | Q3 2023 | -$1.34 | $1.18 | 2.52 | $396.76 M | $750.53 M |
| 08/03/2023 | Q2 2023 | -$1.72 | -$2.21 | -0.49 | $332.28 M | $318.75 M |
| 05/04/2023 | Q1 2023 | -$1.97 | -$1.40 | 0.57 | $312.27 M | $319.29 M |
| 02/23/2023 | Q4 2022 | -$2.13 | -$1.68 | 0.45 | $313.13 M | $335.04 M |
| 10/27/2022 | Q3 2022 | -$1.86 | -$3.32 | -1.46 | $291.66 M | $264.31 M |
| 07/28/2022 | Q2 2022 | -$1.62 | -$2.29 | -0.67 | $255.56 M | $224.82 M |
| 04/28/2022 | Q1 2022 | -$1.93 | -$2.00 | -0.07 | $240.95 M | $213.26 M |
| 02/10/2022 | Q4 2021 | -$1.47 | -$2.16 | -0.69 | $233.61 M | $258.54 M |
| 10/28/2021 | Q3 2021 | -$1.51 | -$1.72 | -0.21 | $218.72 M | $187.63 M |
| 08/03/2021 | Q2 2021 | -$1.57 | -$1.61 | -0.04 | $192.05 M | $220.55 M |
| 04/29/2021 | Q1 2021 | -$1.75 | -$1.71 | 0.04 | $168.50 M | $177.57 M |
| 02/11/2021 | Q4 2020 | -$1.93 | -$2.09 | -0.16 | $146.64 M | $163.56 M |
| 11/05/2020 | Q3 2020 | -$1.75 | -$2.18 | -0.43 | $119.05 M | $125.85 M |
| 08/06/2020 | Q2 2020 | -$1.79 | -$1.56 | 0.23 | $98.76 M | $103.96 M |
Explore Related Stocks for Market Trends
Explore our related stocks for the latest market trends and stock news to stay informed and make better decisions.
Alnylam Pharmaceuticals, Inc. Earnings: FAQ's
Alnylam Pharmaceuticals, Inc. has not confirmed its next earnings publication date, but the company's estimated earnings date is Wednesday, July 30th, 2025 based offlast year's report dates.
In the previous quarter, Alnylam Pharmaceuticals, Inc. (:ALNY) reported $-0.01 earnings per share (EPS) to beat the analysts' consensus estimate of $-0.89002 by $0.88002.
The conference call for Alnylam Pharmaceuticals, Inc.'s latest earnings report can be listened to online.
The conference call transcript for Alnylam Pharmaceuticals, Inc.'s latest earnings report can be read online.
Alnylam Pharmaceuticals, Inc. (:ALNY) has a recorded annual revenue of $2.25 B.
Alnylam Pharmaceuticals, Inc. (:ALNY) has a recorded net income of $-278,157,000.Alnylam Pharmaceuticals, Inc. has generated $-2.16 earnings per share over the last four quarters.
Alnylam Pharmaceuticals, Inc. (:ALNY) has a price-to-earnings ratio of -148.43 and price/earnings-to-growth ratio is -40.26.